Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor
Status:
Unknown status
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
This is a phase I study evaluatingthesafetyand pharmacokinetics of MBS301 after intravenous
administration in patients with HER-2 positive recurrent or metastatic malignant solid
tumors.